Enhanced histone deacetylase enzyme activity in primary myelofibrosis

Jen Chin Wang, Chi Chen, Theresa Dumlao, Seema Naik, Thong Chang, Ying Yi Xiao, Inna Sominsky, Jack Burton

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

We measured histone deacetylase (HDAC) activity in 17 patients with primary myelofibrosis (PMF); 19 with other myeloproliferative neoplasm (MPN) and 16 normal volunteers. Significantly elevated HDAC levels were shown in patients with PMF compared with other MPN patients and normal volunteers (p < 0.05). Sixteen patients with PMF were also studied for correlation between JAK2 mutation status and HDAC levels; no significant correlation was found. We further correlated HDAC levels with clinical features in PMF: there was no correlation with WBC, platelet counts, Hb levels or degree of bone marrow fibrosis, but HDAC levels were correlated to the degree of splenomegaly. This suggests that HDAC may be recruited as essential thrombocythemia or polycythemia vera progresses into myelofibrosis or PMF progresses into more advanced stage. We then used the qRT-PCR cycle threshold (CT) method to study which HDACs were elevated in PMF. The results showed that, in general, Class 1 HDACs were elevated (HDAC1,2,8) except HDAC3, Class II HDACs were depressed (HDAC4,5) except HDAC6 and 10, and Class III HDACs were generally elevated. The current study may form the basis for using HDAC inhibitor in the treatment of patients with PMF and may implicate a possible role of HDAC in the association of pathogenesis of PMF.

Original languageEnglish (US)
Pages (from-to)2321-2327
Number of pages7
JournalLeukemia and Lymphoma
Volume49
Issue number12
DOIs
StatePublished - Dec 16 2008

Fingerprint

Primary Myelofibrosis
Histone Deacetylases
Enzymes
Healthy Volunteers
Essential Thrombocythemia
Polycythemia Vera
Histone Deacetylase Inhibitors
Splenomegaly
Platelet Count
Neoplasms
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Wang, J. C., Chen, C., Dumlao, T., Naik, S., Chang, T., Xiao, Y. Y., ... Burton, J. (2008). Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leukemia and Lymphoma, 49(12), 2321-2327. https://doi.org/10.1080/10428190802527699
Wang, Jen Chin ; Chen, Chi ; Dumlao, Theresa ; Naik, Seema ; Chang, Thong ; Xiao, Ying Yi ; Sominsky, Inna ; Burton, Jack. / Enhanced histone deacetylase enzyme activity in primary myelofibrosis. In: Leukemia and Lymphoma. 2008 ; Vol. 49, No. 12. pp. 2321-2327.
@article{d88043c00c3e4ff7829a92ef6549d519,
title = "Enhanced histone deacetylase enzyme activity in primary myelofibrosis",
abstract = "We measured histone deacetylase (HDAC) activity in 17 patients with primary myelofibrosis (PMF); 19 with other myeloproliferative neoplasm (MPN) and 16 normal volunteers. Significantly elevated HDAC levels were shown in patients with PMF compared with other MPN patients and normal volunteers (p < 0.05). Sixteen patients with PMF were also studied for correlation between JAK2 mutation status and HDAC levels; no significant correlation was found. We further correlated HDAC levels with clinical features in PMF: there was no correlation with WBC, platelet counts, Hb levels or degree of bone marrow fibrosis, but HDAC levels were correlated to the degree of splenomegaly. This suggests that HDAC may be recruited as essential thrombocythemia or polycythemia vera progresses into myelofibrosis or PMF progresses into more advanced stage. We then used the qRT-PCR cycle threshold (CT) method to study which HDACs were elevated in PMF. The results showed that, in general, Class 1 HDACs were elevated (HDAC1,2,8) except HDAC3, Class II HDACs were depressed (HDAC4,5) except HDAC6 and 10, and Class III HDACs were generally elevated. The current study may form the basis for using HDAC inhibitor in the treatment of patients with PMF and may implicate a possible role of HDAC in the association of pathogenesis of PMF.",
author = "Wang, {Jen Chin} and Chi Chen and Theresa Dumlao and Seema Naik and Thong Chang and Xiao, {Ying Yi} and Inna Sominsky and Jack Burton",
year = "2008",
month = "12",
day = "16",
doi = "10.1080/10428190802527699",
language = "English (US)",
volume = "49",
pages = "2321--2327",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

Wang, JC, Chen, C, Dumlao, T, Naik, S, Chang, T, Xiao, YY, Sominsky, I & Burton, J 2008, 'Enhanced histone deacetylase enzyme activity in primary myelofibrosis', Leukemia and Lymphoma, vol. 49, no. 12, pp. 2321-2327. https://doi.org/10.1080/10428190802527699

Enhanced histone deacetylase enzyme activity in primary myelofibrosis. / Wang, Jen Chin; Chen, Chi; Dumlao, Theresa; Naik, Seema; Chang, Thong; Xiao, Ying Yi; Sominsky, Inna; Burton, Jack.

In: Leukemia and Lymphoma, Vol. 49, No. 12, 16.12.2008, p. 2321-2327.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhanced histone deacetylase enzyme activity in primary myelofibrosis

AU - Wang, Jen Chin

AU - Chen, Chi

AU - Dumlao, Theresa

AU - Naik, Seema

AU - Chang, Thong

AU - Xiao, Ying Yi

AU - Sominsky, Inna

AU - Burton, Jack

PY - 2008/12/16

Y1 - 2008/12/16

N2 - We measured histone deacetylase (HDAC) activity in 17 patients with primary myelofibrosis (PMF); 19 with other myeloproliferative neoplasm (MPN) and 16 normal volunteers. Significantly elevated HDAC levels were shown in patients with PMF compared with other MPN patients and normal volunteers (p < 0.05). Sixteen patients with PMF were also studied for correlation between JAK2 mutation status and HDAC levels; no significant correlation was found. We further correlated HDAC levels with clinical features in PMF: there was no correlation with WBC, platelet counts, Hb levels or degree of bone marrow fibrosis, but HDAC levels were correlated to the degree of splenomegaly. This suggests that HDAC may be recruited as essential thrombocythemia or polycythemia vera progresses into myelofibrosis or PMF progresses into more advanced stage. We then used the qRT-PCR cycle threshold (CT) method to study which HDACs were elevated in PMF. The results showed that, in general, Class 1 HDACs were elevated (HDAC1,2,8) except HDAC3, Class II HDACs were depressed (HDAC4,5) except HDAC6 and 10, and Class III HDACs were generally elevated. The current study may form the basis for using HDAC inhibitor in the treatment of patients with PMF and may implicate a possible role of HDAC in the association of pathogenesis of PMF.

AB - We measured histone deacetylase (HDAC) activity in 17 patients with primary myelofibrosis (PMF); 19 with other myeloproliferative neoplasm (MPN) and 16 normal volunteers. Significantly elevated HDAC levels were shown in patients with PMF compared with other MPN patients and normal volunteers (p < 0.05). Sixteen patients with PMF were also studied for correlation between JAK2 mutation status and HDAC levels; no significant correlation was found. We further correlated HDAC levels with clinical features in PMF: there was no correlation with WBC, platelet counts, Hb levels or degree of bone marrow fibrosis, but HDAC levels were correlated to the degree of splenomegaly. This suggests that HDAC may be recruited as essential thrombocythemia or polycythemia vera progresses into myelofibrosis or PMF progresses into more advanced stage. We then used the qRT-PCR cycle threshold (CT) method to study which HDACs were elevated in PMF. The results showed that, in general, Class 1 HDACs were elevated (HDAC1,2,8) except HDAC3, Class II HDACs were depressed (HDAC4,5) except HDAC6 and 10, and Class III HDACs were generally elevated. The current study may form the basis for using HDAC inhibitor in the treatment of patients with PMF and may implicate a possible role of HDAC in the association of pathogenesis of PMF.

UR - http://www.scopus.com/inward/record.url?scp=57449114002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449114002&partnerID=8YFLogxK

U2 - 10.1080/10428190802527699

DO - 10.1080/10428190802527699

M3 - Article

C2 - 19052980

AN - SCOPUS:57449114002

VL - 49

SP - 2321

EP - 2327

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -